

1 **A New Advanced Osteoarthritis Treatment Utilizing Modified Mesenchymal Stem**
2 **Cells: Arthroscopic Guided Intra-Articular Intervention Approach a Systematic Review**
3 **and Meta-Analysis**

4

5 Kevin Christian Tjandra^{1;3},

6 Robin Novriansyah^{2;3},

7 Ardiyana Ar^{1;3},

8 Nurul Azizah Dian Rahmawati^{1;3},

9 I Nyoman Sebastian Sudiasa^{1;3},

10 Ismail Hadisoebroto Dilogo^{4;5;6}

11 ¹Departement of Medicine, Faculty of Medicine, Universitas Diponegoro, Semarang,
12 Indonesia

13 ²Department of Surgery, Faculty of Medicine, Universitas Diopnegoro, Semarang, Indonesia

14 ³Kariadi General Hospital, Semarang, Indonesia

15 ⁴Stem Cell Medical Technology Integrated Service Unit, Cipto Mangunkusumo Central
16 Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia

17 ⁵Stem Cell and Tissue Engineering Research Cluster Indonesian Medical Education and
18 Research Institute (IMERI) Universitas Indonesia, Jakarta, Indonesia

19 ⁶Department of Orthopaedic and Traumatology, Cipto Mangunkusumo General Hospital,
20 Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia

21

22 Correspondence:

23 Ismail Hadisoebroto Dilogo, MD, PhD, Stem Cell Medical Technology Integrated Service
24 Unit, Cipto Mangunkusumo Central Hospital, Faculty of Medicine Universitas Indonesia,
25 CMU 2 Building, Kimia Street No. 40, Jakarta, Indonesia.

26 Email: ismailortho@gmail.com

27

28 **Abstract**

29 **Background:** *The mesenchymal stem cells (MSCs) is able to regenerate the cartilage defect*
30 *caused by osteoarthritis (OA) to prevent permanent disability. Its efficacy may be even*
31 *greater in combination with platelet-rich plasma (PRP) and hyaluronic acid (HA). Thus, this*
32 *systematic review aimed to investigate the efficacy of MSCs in combination with PRP and*
33 *adjusted doses of HA, the best source of MSCs, and the optimal number of applied MSCs to*
34 *treat osteoarthritis as a cartilage regenerative agent. **Method:** The sources included were*
35 *original articles published from 2013 until 2023 from 4 databases (Pubmed, Springerlink,*
36 *ScienceDirect, and Google Scholar). Studies included were original research of clinical*
37 *trials or randomized controlled trials. Irrelevant studies were excluded. Then, the ROB-2*
38 *taken was used to assess bias. The result was constructed with PICOS criteria within the*
39 *table created in the Google spreadsheet. MRI score, VAS score, Lysholm score, Cartilage*
40 *volume, size of cartilage defect, Knee Society Clinical Rating System Score (KSS), and*

41 WOMAC index to evaluate treatment's efficacy outcomes were analyzed by Revman 5.4.
42 This systematic review followed the PRISMA guidelines. **Result:** nine studies were included
43 in the final screening. The meta-analysis showed a significant ($P < 0.00001$) elevation of
44 Lysholm score with a pooled mean difference (MD) of (17.89) (95% CI: 16.01, 19.77; $I^2 =$
45 0%, $P = 0.56$); a significant reduction ($P < 0.00001$) of VAS score with a pooled MD of (-
46 2.62) (95% CI: -2.83, -2.41; $I^2 = 99%$, $P < 0.00001$); Knee society clinical rating system
47 score (KSS) evaluation also showed significant elevation ($P < 0.00001$) with mean pooled
48 (29.59) (95% CI: 27.66, 31.52; $I^2 = 95%$, $P < 0.0001$); and significantly reduction ($P <$
49 0.00001) of WOMAC score occurred as pooled MD of (-12.38) (95% CI: -13.75, -11.01; $I^2 =$
50 $99%$, $P < 0.0001$). **Conclusions:** Arthroscopic guided high- dose subchondral application of
51 primary cultured synovial mesenchymal stem cells in popliteal platelet-rich plasma media
52 combined with hyaluronic acid effectively regenerate cartilage defect and increase clinical
53 outcomes in the early stage of osteoarthritis.

54

55 **Keywords:** Synovial mesenchymal stem cells, Osteoarthritis, Intra-articular intervention

56 **Level of Evidence:** Therapeutic Level I.

57 **Introduction**

58 Osteoarthritis is a chronic inflammatory joint disease due to the degradation of the cartilage
59 that causes joint pain and limitation in movement [1]. Over three decades, the global
60 prevalence of OA increased by 113.25% from 1990-2019 with an estimated 527.81 million
61 people [2]. The pathogenesis of OA is complex due to the multifactorial factors that can
62 influence the occurrence and progression of the disease, including genetic, cellular,
63 biochemical, and immunological. However, the main pathogenesis pathway that worsens the

64 OA condition is the calcification of the cartilage defect. Thus, cartilage repair may prevent
65 the progression of osteoarthritis [3][4].

66 The pharmacological conservative therapy does not provide significant benefits and the side
67 effects that can arise also need to be considered in its application [5]. Furthermore,
68 pharmacotherapy itself is not able to solve the main problem of OA, cartilage damage.

69 Surgical techniques such as total knee replacement can be performed but the risk of persistent
70 pain or loss of joint function reaches 20% [6]. Thus, less invasive procedure with promising
71 result is needed to treat OA.

72 Mesenchymal stem cells (MSCs) as the regenerative agent is one of the solution of knee OA
73 treatment because of its ability to regenerate cartilage defect [7]. Among various MSC
74 sources, synovial MSC is a promising cell source for cartilage repair. Synovial MSCs have
75 superior chondrogenic ability compared to MSCs from other tissues [8]. Synovial tissue has
76 the greatest potential for differentiation into chondrogenic cells and proliferation. The
77 synovium is a thin membrane that covers the inside of the joint and has a high regenerative
78 activity. According to previous studies, the amount of MSCs in synovial fluid is increased in
79 knees with OA that proving its regeneration activity [9]. Transplantation of large numbers of
80 synovial MSCs into injured cartilage tissue can enhance the natural healing process. From
81 previous studies, synovial MSCs were transplanted arthroscopically and led patients to return
82 to daily life and sports activities earlier than patients with invasive surgery [8]. Therefore, this
83 systematic review aimed to investigate the efficacy of MSCs in combination with PRP and
84 adjusted doses of HA, the best source of MSCs, and the optimal number of applied MSCs to
85 treat osteoarthritis as a cartilage regenerative agent.

86

87 **Material and Method**

88 *Registration*

89 The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) were
90 used for this systematic review [10]. On August 8, 2023, this systematic review and meta-
91 analysis was registered to the Open Science Framework (OSF).

92 *Eligibility criteria*

93 From 2013 until 2023 (the last date for which a search was conducted was 22 May 2023), we
94 have included original content. The study included original research publications that met the
95 inclusion criteria for autologous clinical trials and randomized controlled trials (RCT).
96 Technical reports, editor answers, narrative reviews, systematic reviews, meta-analyses, non-
97 comparative research, in silico studies, in vitro studies, in vivo studies, scientific posters,
98 study protocols, and conference abstracts were all discarded. Non-English, non-full-text, and
99 unrelated papers that were not related to the application of MSCs to treat knee osteoarthritis
100 were also removed. The desired PICO criteria of the selected articles including i) patient with
101 osteoarthritis or cartilage damage; ii) Intervention of intra-articular intervention or
102 arthroscopic guided MSCs application; iii) Comparison, standard care without synovial stem
103 cell application (placebo); and iv) Outcomes, treatment's evaluation of AMADEUS MRI
104 score for cartilage defect, VAS score, Lysholm score, Cartilage volume, size of cartilage
105 defect, Knee Society Clinical Rating System Score (KSS), and WOMAC index.

106 *Outcome measure*

107 The efficacy evaluation of the therapy was then assessed by several outcomes including MRI
108 score, VAS score, Lysholm score, Cartilage volume, size of cartilage defect, Knee Society
109 Clinical Rating System Score (KSS), and WOMAC index. The AMADEUS MRI score for

110 cartilage defects was assessed before and after treatment to know the cartilage regeneration;
111 the VAS score was used to assess the clinical pain before and after treatment; the Lysholm
112 score was used to assess the symptom of disability; then the WOMAC index has a role to
113 assess the severity clinical problem in osteoarthritis patients; and KSS is used to evaluate rate
114 the knee and patient's functional abilities.

115

116 Index Test

117 Studies that provided data on the application and evaluations of bone membrane
118 mesenchymal stem cells in osteoarthritis are included in this systematic review and meta-
119 analysis.

120

121 Reference Standard

122 Reference standards are professional research using randomized controlled clinical studies
123 (RCT) or clinical trials to assess the transition of mesenchymal stem cells in osteoarthritis
124 outcomes.

125

126 Data Sources and Search

127 Research for this study was gathered through Pubmed, Springerlink, Google Scholar, and
128 Science Direct database searches. The database was searched from its establishment until 22
129 May 2023 during 10-year periods prior to this review. The Boolean operator was utilized
130 among the Medical Subject Headings (MeSH) keywords determined from the national
131 institute of Health (NIH) National Library of medicine browser. In **Table 1**, the keywords
132 used in each database are displayed. The studies are kept using Mendeley Group Reference
133 Manager in the authors' library. Clinical trial and randomized controlled trial type articles

134 were used as a filter in the Pubmed database, the content-type article was used as the Springer
135 database filter, the research article type was used for the Science Direct database filter, and
136 any type of article was used in Google Scholar. A total of 5,101 studies were found in the
137 database (4478 from Springerlink, 521 from Pubmed, 70 from Google Scholar, and 32 from
138 Science Direct). 561 studies were imported to the Mendeley Group Reference Manager in the
139 authors' library after the aforementioned criteria were added, and this was done before the
140 selection procedure.

141

142 **Table 1.** Keyword Used in Literature Searching

143

Database	Keywords
Pubmed	Osteoarthritis and Synovial Membrane and Stem Cell
Springerlink	
Science Direct	
Google Scholar	

144

145 *Selection process*

146 Four independent reviewers (KCT, AA, NADR, and INSS) and one validator (RN) combined
147 the outcomes from four databases after applying the search keywords indicated in Table 1.
148 After that, they conducted a complete text and abstract screening to exclude non-clinical trial
149 and non-randomized controlled trial papers while keeping the pertinent ones. 534 studies
150 were eliminated from this process because they did not provide sufficient data to answer the

151 research question (application and evaluations of MSCs in osteoarthritis) and because their
152 study designs did not meet the criteria for inclusion (clinical trial and randomized controlled
153 trial) and 16 studies were removed due to duplication. The retrieval of the complete text for
154 the remaining 11 studies were then tested. Only 10 full text articles could be obtained as a
155 result. Then, utilizing the title, year of publication, and DOIs, one publication was eliminated
156 due to irrelevant outcome of interest. Using the Cochrane Risk of Bias 2 For Randomized
157 Trials (ROB-2) tool, the nine included studies were evaluated for eligibility. All nine of the
158 listed studies from this process passed the evaluation bias check. The PRISMA flow chart
159 contained records of the research selection procedures.

160

161 Data collection process

162 After the final screening, the pertinent information from studies is retrieved and entered into a
163 Google Spreadsheet. Recorded data in characteristic table consists of author, year, country,
164 study design, sample size, gender, mean age, intervention name, comparison, and outcome
165 consisting of the AMADEUS MRI score for cartilage defect, VAS score, WOMAC Index,
166 Cartilage volume, size of cartilage defect, Knee Society Clinical Rating System Score (KSS).

167

168 Study Risk of Bias assessment (Qualitative Synthesis)

169 Risk-of-bias tool used to assess the bias of included studies was the Cochrane risk-of-bias
170 tool for randomized trials (RoB-2) which can be accessed in
171 ([https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-](https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials)
172 [randomized-trials](https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials)), was used by five independent reviewers (KCT, RN, AA, NADR, INSS,
173 and IHD). Any disagreements regarding the bias assessment were discussed further and
174 settled between the 5 reviewers. Papers deemed with a high risk of bias will be removed from

175 the systematic review to preserve the validity of included data in the current study as shown
176 in.

177

178 Reporting bias assessment

179 As the result of ROB-2 assessment bias conducted by KCT, AA, NADR, INSS, and RN, all
180 nine included articles did not show any critical overall bias as mentioned in Figure 1 so no
181 article was removed at this stage.

182

183 Quantitative Synthesis

184 Outcomes were presented in the form of mean difference (MD) and standard deviation (SD)
185 with a confidence interval (CI) of 95% in the characteristic table. Meta-analysis was used
186 with a fixed-effect model (FEM) when the included studies were considered homogenous
187 (low variability in studies' results or variation due to random error), which was indicated by
188 an I^2 value of less than 40%. Otherwise, we used a random-effect model (REM). The pooled
189 mean difference estimate was presented in a forest plot.

190


191 **Result**

192 Study Selection

193 A literature search utilizing Springerlink, Pubmed, Google Scholar, and ScienceDirect
194 resulted in 5,101 papers overall. Automation approaches from each database were used to
195 exclude non-clinical trials and non-randomized controlled trial research, which resulted in the

196 elimination of 4,540 articles. After writers checked each and every article for relevancy and
197 duplication starting with the title and abstract, 534 irrelevant subjects and 16 duplicate
198 articles were eliminated. The inability to get the complete text document caused 1 unretrieved
199 item to be eliminated. Then, 1 irrelevant outcome of interest research papers were eliminated.
200 The full texts of nine articles were subsequently acquired. Last but not least, the author
201 determined each study's eligibility, and all nine studies met the requirements. This systematic
202 review and meta-analysis include nine articles. The flow chart for the PRISMA diagram
203 illustrating our research selection procedure is shown in Figure 1.

PRISMA 2020 flow diagram for new systematic reviews which included searches of databases and registers only



204

205 **Figure 1.** PRISMA 2020 flow diagram.

206 Study Characteristics

207 The nine studies that made up this systematic review comprised a total of 315 participants.
 208 Each four studies were conducted in different countries. Studies were carried out in Japan,
 209 South Korea, France, China, USA, Iran, Singapore, and Spain. The complete study
 210 characteristics, including the PICO of each study, are stated in **Table 2**.

211 Risk of Bias in Studies

212 Each clinical trial and randomized controlled trial study underwent a thorough assessment of
 213 its quality using the ROB-2 risk-of-bias method. In nine of the investigations, there were 3
 214 studies identified as a study with some concern of bias due to unclear randomization process
 215 between the allocation of intervention and control group. An overview of the bias risk
 216 assessment is shown in Figure 2.

StudyID	Experimental	Comparator	Outcome	Weight	D1	D2	D3	D4	D5	Overall	
Sekiya, et al; 2015	NA	NA	NA	1	I	+	+	+	I	I	+
Hyunchul C, et al; 2014	NA	NA	NA	1	I	+	I	+	+	I	+
Hernigou P, et al; 2020	NA	NA	NA	1	+	+	+	+	+	+	+
Xu z, et al; 2020	NA	NA	NA	1	I	+	+	I	+	I	+
Garza JR, et al; 2020	NA	NA	NA	1	+	+	+	+	+	+	+
Emededin M, et al; 2012	NA	NA	NA	1	I	I	+	+	I	I	+
Hyunchul C, et al; 2017	NA	NA	NA	1	+	+	+	+	+	+	+
Wong KL, et al; 2013	NA	NA	NA	1	+	+	+	+	+	+	+
Espinosa JMI, et al; 2016	NA	NA	NA	1	+	+	+	+	+	+	+

217

- + Low risk
- I Some concerns
- High risk

- D1 Randomisation process
- D2 Deviations from the intended interventions
- D3 Missing outcome data
- D4 Measurement of the outcome
- D5 Selection of the reported result

218 **Figure 2.** Risk of Bias Assessment


219 Study Result Summaries

220 The journal selection method that has been carried out produced four studies that were used
 221 in the systematic review and meta-analysis process. The nine studies were conducted by

222 Sekiya et al. (2015), Hyunchul C et al. (2014), Hernigou et al. (2020) Xu Z et al. (2020),
 223 Garza JR et al. (2020), Emededin M et al. (2012), Hyunchul C et al. (2017), Wong KL et al.
 224 (2013), Espinosa JML, et al. (2016). Brief profiles of the nine studies are shown in Table 2.

225 Lysholm score

226 The disability symptoms caused by OA were assessed based on Lysholm’s score in the
 227 questionnaires of the respective standardized tools. A meta-analysis of two studies assessed
 228 the efficacy of OA synovial fluid stem cells in relieving disability symptoms in the pre-
 229 intervention and post-intervention groups. The forest plot in Figure 3 depicts a significant
 230 effect ($P < 0.00001$) with a pooled mean difference (MD) of (17.89) (95% CI: 16.01, 19.77).
 231 This result indicates that synovial fluid stem cell was found to decrease Lysholm score in OA
 232 patients significantly. The forest plot also showed heterogeneity was found ($I^2 = 0\%$; P
 233 < 0.00001) for the efficacy of synovial fluid stem cells in relieving the disability symptoms in
 234 OA patients.




236 **Figure 3.** Forest plot of Lysholm score between intervention vs control group

237 Visual Analog Scale (VAS)

238 Clinical pain experienced by OA patients is assessed with VAS scores which are shown in
 239 Figure 4. A meta-analysis included three studies that analyzed the efficacy of synovial fluid
 240 stem cells in reducing clinical pain in OA patients. The forest plot showed a significant effect
 241 ($P < 0.00001$) with a pooled MD of -2.62 (95% CI: -2.83, -2.41). The pooled MD shows that

242 mesenchymal stem cell is significantly effective in reducing clinical pain in OA patients.

243 Heterogeneity was found ($I^2 = 0\%$; $P = <0.00001$).



244

245 **Figure 4.** Forest plot of VAS score between intervention vs control group


246 Knee Society Clinical Rating System Score (KSS)

247 Knee function and ability in OA patients is assessed with KSS scores as shown in Figure 5.

248 The forest plot using KSS showed a significant effect ($P < 0.00001$) with a pooled MD of

249 29.59 (95% CI: 27.66, 31.52). The pooled MD shows mesenchymal stem cells significantly

250 improved knee function and ability. Heterogeneity was found ($I^2 = 95\%$; $P < 0.00001$).



251

252 **Figure 5.** Forest plot of KSS score between intervention and control group.

253 WOMAC Score


254 Symptoms in OA patients is assessed with WOMAC score as shown in Figure 6. The forest

255 plot analyzing WOMAC score showed a significant effect ($P < 0.00001$) with a pooled MD

256 of -12.38 (95% CI: -13.75, -11.01). The pooled MD shows mesenchymal stem cells

257 significantly relieve symptoms in OA patients. Heterogeneity was found ($I^2 = 99\%$; $P <$

258 0.00001).



259

260 **Figure 6.** Forest plot of WOMAC score between intervention and control group.

261 **Discussion**

262 **Synovial Mesenchymal Stem Cell**

263 Synovial Mesenchymal Stem Cells (Sy-MSCs) originate from the mesenchyme,
 264 which is an embryonic connective tissue that gives rise to various types of cells, including
 265 bone, cartilage, and adipose tissue. Synovial MSCs have the ability to self-renew and
 266 differentiate into several types of cells from the mesenchymal lineage, including osteoblasts
 267 (bone cells), synovial (cartilage cells), and adipocytes (fat cells) [11]. They also exhibit
 268 immunomodulatory properties, meaning they can regulate the immune response. Synovial
 269 MSCs can be isolated from synovial fluid or the synovial membrane/tissue of joints such as
 270 the knee, hip, or shoulder. Various methods, including aspiration or biopsy, can be used to
 271 obtain these cells [12].

272 Synovial MSCs have garnered significant interest in regenerative medicine and tissue
 273 engineering due to their ability to differentiate into different cell types [13]. It has been
 274 shown that Sy-MSCs had a greater proliferation capacity and stronger chondrogenic potential
 275 than Bone Marrow-MSCs and Adipose Tissue-MSCs, as well as less hypertrophic
 276 differentiation than bone Bone Marrow-MSCs. In addition, pellet cultures were significantly
 277 larger from Sy-MSC than Bone Marrow-MSCs in patient-matched comparisons. They hold

278 promise for the repair and regeneration of damaged or diseased joint tissues, such as cartilage
279 and bone. They are being explored as potential treatments for conditions such as
280 osteoarthritis, rheumatoid arthritis, and joint injuries [14].

281 Synovial MSCs play an important role in the pathophysiology and treatment of
282 osteoarthritis (OA). In osteoarthritis, the synovial membrane undergoes changes, including
283 inflammation and hyperplasia [15]. Synovial MSCs participate in the repair and maintenance
284 of joint tissues, including articular cartilage. However, in OA, the regenerative capacity of
285 synovial MSCs is often impaired due to factors such as aging, inflammation, and abnormal
286 joint microenvironment. Synovial MSCs have chondrogenic potential, meaning they can
287 differentiate into chondrocyte-like cells responsible for producing and maintaining the
288 cartilage matrix [16][17][18].

289 Synovial MSCs hold promise for the treatment of OA. They can be isolated from
290 synovial fluid or the synovial membrane through minimally invasive procedures [19]. These
291 cells can be expanded in the laboratory and then transplanted back into the joint to promote
292 tissue repair and regeneration.

293 **Application of Synovial Stem Cell in Treating Osteoarthritis**

294 Osteoarthritis may develop as a result of articular cartilage injuries, which are a common
295 clinical issue. Despite the variety of surgical intervention techniques, each has disadvantages
296 of its own: Bone marrow stimulation results in poor structural quality of the repaired
297 cartilage, donor site morbidity in mosaicplasty, and loss of the chondrogenic phenotype of
298 expanded chondrocytes in autologous chondrocyte implantation [20]. One potential method
299 for enhancing cartilage injury repair is stem cell therapy. Mesenchymal stem cells (MSCs),

300 which can be isolated from various mesenchymal tissues, especially synovial membranes are
301 one of the potential therapeutic cells.

302 The potential of synovial MSCs can be maximized by combining with other intraarticular
303 regeneration agents, including, Platelet-Rich Plasma and hyaluronic acid [21]. This
304 combination might be a great solution to treat cartilage damage in Osteoarthritis and prevent
305 the overuse of hyaluronic acid that fastens the OA disease progression. A small amount of
306 hyaluronic acid intraarticular application is able to stimulate cartilage regeneration. However,
307 this small amount of HA is not enough to stop the disease progression, but the more
308 hyaluronic acid is used the more VEGF production occurs. The high amount of VEGF will
309 calcify the cartilage and convert it into osteocytes which worsen osteoarthritis [22].

310 Among all 4 Kellgren Lawrence classifications, this non-operative treatment is useful in OA
311 grades 1 - 3. The earlier stage the greater outcome will be obtained [23]. It is because of this
312 treatment strategy, that Modified Synovial Mesenchymal Stem Cells act as a cartilage
313 regenerative agent that prevents further OA progression [8].

314 Cellaid1 (JMS Co Ltd, Hiroshima, Japan), a closed-bag system for serum isolation, was used
315 to collect 300 mL of whole blood from the patient's knee intraarticular, obtained by
316 microfracture; fat pad severe; and suprapatellar pouch severe, one or two days prior to the
317 harvest of synovial tissue. The popliteal vein is preferred due to its protein-rich plasma or
318 autologous serum being suitable for the synovial stem cell culture process. The system
319 consists of a blood donation bag filled with glass beads that, over 30 minutes of gentle
320 mixing, activate platelets and remove fibrin from whole blood. The serum was isolated and
321 heat-inactivated at 56° C for 30 minutes, following centrifugation at 2000 g for 7 minutes.

322 Before use, the serum was stored at 4° C after filtering through a 0.45- μ m nylon filter from
323 Becton Dickinson, Franklin Lakes, New Jersey, USA [24].

324 The related Patients then underwent arthroscopy under the effects of local anesthesia
325 containing 20 mL of 1% xylocaine. The synovium with sub synovial tissue on the femur at
326 the suprapatellar pouch was then harvested with a pituitary rongeur under arthroscopic
327 supervision while the patient was under intravenous anesthesia with 0.1 g sodium pentothal.
328 After the synovial MSCs were harvested, patients were able to leave the hospital during the
329 culture period [8].

330 The harvested synovial MSCs then digested using a solution of 5 mg Liberase in 5 ml Hanks'
331 balanced salt solution for 3 hours. Then the result was filtered through a 70- μ m nylon filter to
332 obtain the target synovial MSCs. The cells were grown in a-MEM from Invitrogen, which
333 contained 10% autologous human serum, 100 units/mL of penicillin, 100 μ g/mL of
334 streptomycin, and 250 ng/mL of amphotericin B. In total, 50 dishes were examined on day 12
335 to look for bacteria, endotoxins in the medium, mycoplasma, and viruses in the cells.
336 Chocolate agar was utilized for bacterial testing. A Toxicolor1 LS-50M kit (Seikagaku
337 Corporation, Tokyo, Japan) was used for endotoxin testing. A multiplex PCR system created
338 by our team was utilized for testing for mycoplasma and viruses [6]. This system detected 17
339 different virus types and 142 different mycoplasma types. Chromosomal testing was also
340 conducted using one dish [25][26].

341 After no harmful contamination was confirmed, the synovial MSCs were harvested at day 14
342 using TrypLE at 37°C for 5 minutes. Primary synovial MSCs were suspended in 0.5 mL of
343 acetate Ringer's solution 30 minutes prior to transplantation. 47 million \pm 21 million
344 transplanted cells (mean \pm SD) were used [27].

345 For the transplant, the patient was positioned with the cartilage defect facing upward, and
346 using an 18-gauge needle and a 1-mL syringe, a suspension of synovial MSCs in 0.5 mL of
347 acetate Ringer's solution was injected into the defect under arthroscopic supervision. The
348 defect was then held in the upward position for 10 minutes with the applied suspension. After
349 10 minutes, the additional 0.25 ml might be added to the cartilage defect in order to reduce
350 synovial inflammation and reduce pain after the procedure [28].

351 Following surgery, all patients began knee ROM exercises. After two weeks and six weeks,
352 they could bear total weight. There was no use of specialized machinery like a continuous
353 passive motion machine. Generally, low-impact activities could begin at three months and
354 high-impact activities at six. Then, the outcome evaluation was assessed using MRI, Lysholm
355 score and Visual Analog Scale (VAS).

356

357 **Effication of MSCs in Treating Osteoarthritis**

358 In recent years, the potential use of mesenchymal stem cells as a therapeutic approach for OA
359 has gained significant attention. Compared to conventional bone marrow MSCs, Synovial
360 mesenchymal stem cell (SFCs) has more efficacy as proven in the study conducted by
361 Sekiya, et al. (2015) [8]. It's because synovial fluid cells have more similarity in synovial
362 environment than other sources of cells. Thus, it can exhibit multipotency where each cell can
363 differentiate into various cell types including chondrocytes, which are crucial for the
364 maintenance and repair of cartilage. The regenerative properties of SFSCs are important in a
365 joint inflammation disease such as osteoarthritis. A study by Kim et al. (2019) demonstrated
366 that SFSCs derived from OA patients could differentiate into chondrogenic lineage cells and
367 promote cartilage matrix formation [29]. Moreover, another study by Qiu et al. (2021)

368 reported that SFSCs combined with hyaluronic acid injections resulted in improved cartilage
369 regeneration and enhanced functional outcomes in a rabbit model of OA [30]. Then, the
370 efficacy of this treatment can be maximized by the application of appropriate high-dose
371 MSCs (1×10^8 cells) with subchondral technique compared to intra-articular injection as
372 proven by a study conducted by Hernigou P, et al. (2020)[31].

373 However, studies exploring the efficacy of SFSCs in human trials are still relatively limited.
374 A phase I/II clinical trial conducted by Jo et al. (2019) involved intra-articular injection of
375 SFSCs in patients with knee OA [32].

376 This study reported significant improvements in pain, function, and cartilage quality,
377 demonstrating the potential of MSCs as a new treatment modality for OA. Studies conducted
378 by Sekiya et al. (2015) and Xu, et al. (2020) has proven elevation of the Lysholm score va
379 which assesses disability in OA patients proved to be statistically significant ($P < 0.001$)
380 increased by pooled MD (17.89) [95% CI:16.01, 19.77] compared to the control group [8]
381 [33].

382 In addition, MSCs were also proven to be significantly effective in reducing VAS scores as
383 proven by studies conducted by Emededin M, et al. (2012), Hyunchul, et al. (2017), and Xu
384 Z, et al. (2020) showed the statistical effectiveness of Intra-articular Injection of Autologous
385 MSCs ($P < 0.00001$) with pooled MD (-2.62) (95% CI: -2.83, -2.41) [34] [35] [33]. Proven by
386 MRI images, post-injection cartilage thickness increased in three of the six patients. Xu et al.
387 (2020) showed that the efficacy of intra-articular platelet-rich plasma (PRP) SFSC would
388 increase when combined with hyaluronic acid and (PRP) as demonstrated by a significant
389 reduction in VAS scores in the PRP+HA group at 24 months afterward. injection, PRP+HA
390 was more effective than HA and PRP alone in relieving pain ($P = 0.0001$) [33]. In addition,

391 significant improvements were also observed in the PRP+HA group after 1, 6, 12, and 24
392 months ($P < 0.0001$).

393 MSCs can also improve the WOMAC index which assesses the severity of clinical problems
394 in osteoarthritis patients. The results of the study by Emededin, et al. (2012), Espinosa, et al.
395 (2016), Garza, et al. (2020), Hyunchul, et al. (2014), Hyunchul, et al. (2017), and Xu, et al.
396 (2020) showed a clinically meaningful reduction of WOMAC score as much pooled MD (-
397 12.38) (95% CI: -13.75, -11.01) [34][36][37][38][35]. In addition, KSS function score
398 evaluation from Hernigou, et al. (2020), Hyunchul, et al. (2014), and Hyunchul, et al. (2017)
399 increased significantly from as much pooled MD (29.59) (95% CI: 27.66, 31.52)
400 [31][35][38].

401

402 **Strength and Limitation**

403 This study is the first systematic review and meta-analysis that assessed the efficacy of
404 synovial fluid stem cell in treating osteoarthritis. This study also included studies from
405 various countries showing this therapy's universal applicability. Although this study also has
406 several limitations such as the limited number of included studies.

407

408 **Conclusion**

409 Arthroscopic guided injection of primary cultured synovial mesenchymal stem cells in
410 popliteal platelet-rich plasma media combined with hyaluronic acid is effectively regenerate
411 cartilage defect in the early stage of osteoarthritis and reduce synovial inflammation that may

412 cause knee pain. Synovial mesenchymal stem cells have also been proven to not cause any
413 side effects in osteoarthritis patients.

414

415 **Recommendation**

416 More studies need to be conducted to further evaluate the duration and efficacy of the
417 synovial mesenchymal stem cell as a novel therapy for osteoarthritis.

418

419 **Data availability**

420 *Underlying data*

421 All data underlying the results are available as part of the article and no additional source data
422 are required.

423 *Reporting guidelines*

424 Mendeley Data: A New Advanced Osteoarthritis Treatment Utilizing Modified Synovial
425 Mesenchymal Stem Cells: Arthroscopic Guided Intra-Articular Intervention Approach a
426 Systematic Review and Meta-Analysis. doi: 10.17632/zn8t3gks5g. .

427 Data are available under the terms of the [Creative Commons Attribution 4.0 International](#)
428 [license](#) (CC-BY 4.0).

429

430 **Funding**

431 The author(s) declared no funding information available.

432

433 **Competing interests**

434 No competing interests were disclosed.

435

436 **Grant information**

437 The author(s) declared that no grants were involved in supporting this work.

438

439

440

441

442 **Reference**

- 443 1. Miller A, Lutsky KF, Shearin J, Cantlon M, Wolfe S, Beredjiklian PK. Radiographic
444 Patterns of Radiocarpal and Midcarpal Arthritis. *J Am Acad Orthop Surg Glob Res*
445 *Rev.* 2017 Jun;1(3):e017.
- 446 2. Long H, Liu Q, Yin H, Wang K, Diao N, Zhang Y, et al. Prevalence Trends of Site-
447 Specific Osteoarthritis From 1990 to 2019: Findings From the Global Burden of
448 Disease Study 2019. *Arthritis Rheumatol.* 2022;74(7):1172–83.
- 449 3. Dobson GP, Letson HL, Grant A, McEwen P, Hazratwala K, Wilkinson M, Morris JL.
450 Defining the osteoarthritis patient: back to the future. *Osteoarthritis Cartilage.* 2018
451 Aug;26(8):1003-1007.
- 452 4. Stewart HL, Kawcak CE. The Importance of Subchondral Bone in the
453 Pathophysiology of Osteoarthritis. *Front Vet Sci.* 2018;5:178.
- 454 5. Kloppenburg M, Berenbaum F. Osteoarthritis year in review 2019: epidemiology and
455 therapy. *Osteoarthr Cartil [Internet].* 2020;28(3):242–8. Available from:
456 <https://doi.org/10.1016/j.joca.2020.01.002>
- 457 6. Wylde V, Hewlett S, Learmonth ID, Dieppe P. Persistent pain after joint replacement:
458 prevalence, sensory qualities, and postoperative determinants. *Pain.* 2011;152(3):566-
459 572. doi:10.1016/j.pain.2010.11.023.
- 460 7. Sergijenko A, Roelofs AJ, Riemen AHK, De Bari C. Bone marrow contribution to
461 synovial hyperplasia following joint surface injury. *Arthritis Res Ther.* 2016 Jul
462 13;18(1).
- 463 8. Sekiya I, Muneta T, Horie M, Koga H. Arthroscopic Transplantation of Synovial Stem

- 464 Cells Improves Clinical Outcomes in Knees With Cartilage Defects. *Clin Orthop Relat*
465 *Res.* 2015 Jul 8;473(7):2316–26.
- 466 9. Sekiya I, Ojima M, Suzuki S, et al. Human mesenchymal stem cells in synovial fluid
467 increase in the knee with degenerated cartilage and osteoarthritis. *J Orthop Res.*
468 2012;30(6):943-949. doi:10.1002/jor.22029.
- 469 10. Tjandra, K. C., Novriansyah, R., Ar, A., Rahmawati, N. A. D., Sudiasa, I. N. S., &
470 Dologo, I. H. (2023, August 5). A New Advanced Osteoarthritis Treatment Utilizing
471 Modified Synovial Mesenchymal Stem Cells: Arthroscopic Guided Intra-Articular
472 Intervention. <https://doi.org/10.17605/OSF.IO/HS4RZ>
- 473 11. Fellows CR, Matta C, Zakany R, Khan IM, Mobasher A. Adipose, Bone Marrow and
474 Synovial Joint-Derived Mesenchymal Stem Cells for Cartilage Repair. *Front Genet.*
475 2016;7:213. Published 2016 Dec 20. doi:10.3389/fgene.2016.00213.
- 476 12. Sokolove J, Lepus CM. Role of inflammation in the pathogenesis of osteoarthritis:
477 latest findings and interpretations. *Ther Adv Musculoskelet Dis.* 2013;5(2):77-94.
478 doi:10.1177/1759720X12467868.
- 479 13. Fan J, Varshney RR, Ren L, Cai D, Wang DA. Synovium-derived mesenchymal stem
480 cells: a new cell source for musculoskeletal regeneration. *Tissue Eng Part B Rev.*
481 2009;15(1):75-86. doi:10.1089/ten.teb.2008.0586.
- 482 14. Li J, Long X, Ke J, Meng QG, Fang W. *Zhonghua Kou Qiang Yi Xue Za Zhi.*
483 2005;40(5):362-364.
- 484 15. Kong L, Zheng LZ, Qin L, Ho KKW. Role of mesenchymal stem cells in osteoarthritis
485 treatment. *J Orthop Translat.* 2017;9:89-103. Published 2017 Apr 12.

- 486 doi:10.1016/j.jot.2017.03.006.
- 487 16. Pasculli RM, Kenyon CD, Berrigan WA, Mautner K, Hammond K, Jayaram P.
488 Mesenchymal stem cells for subchondral bone marrow lesions: From bench to bedside.
489 Bone Rep. 2022;17:101630. Published 2022 Oct 21. doi:10.1016/j.bonr.2022.101630.
- 490 17. Danišovič L, Varga I, Polák S. Growth factors and chondrogenic differentiation of
491 mesenchymal stem cells. Tissue Cell. 2012;44(2):69-73.
492 doi:10.1016/j.tice.2011.11.005.
- 493 18. López-García L, Castro-Manreza ME. TNF- α and IFN- γ Participate in Improving the
494 Immunoregulatory Capacity of Mesenchymal Stem/Stromal Cells: Importance of Cell-
495 Cell Contact and Extracellular Vesicles. Int J Mol Sci. 2021;22(17):9531. Published
496 2021 Sep 2.
- 497 19. Li N, Gao J, Mi L, Zhang G, Zhang L, Zhang N, et al. Synovial membrane
498 mesenchymal stem cells: past life, current situation, and application in bone and joint
499 diseases. Stem Cell Res Ther. 2020;11:1–12. Available from:
500 <https://www.proquest.com/scholarly-j>.
- 501 20. Mollon B, Kandel R, Chahal J, Theodoropoulos J. The clinical status of cartilage tissue
502 regeneration in humans. Osteoarthritis Cartilage. 2013;21(12):1824-1833.
503 doi:10.1016/j.joca.2013.08.024.
- 504 21. Tucker JD, Goetz LL, Duncan MB, Gilman JB, Elmore LW, Sell SA, et al.
505 Randomized, Placebo-Controlled Analysis of the Knee Synovial Environment
506 Following Platelet-Rich Plasma Treatment for Knee Osteoarthritis. PM R. 2021 Jul
507 1;13(7):707–19.

- 508 22. Bellini MR. Mitogen Inducible Gene-6 in Joint Health and Osteoarthritis [Internet].
509 ProQuest Dissertations and Theses. [Canada -- Ontario, CA]: The University of
510 Western Ontario (Canada) PP - Canada -- Ontario, CA; 2020. Available from:
511 [https://www.proquest.com/dissertations-theses/mitogen-inducible-gene-6-joint-](https://www.proquest.com/dissertations-theses/mitogen-inducible-gene-6-joint-health/docview/2717697236/se-2?accountid=49069)
512 [health/docview/2717697236/se-2?accountid=49069](https://www.proquest.com/dissertations-theses/mitogen-inducible-gene-6-joint-health/docview/2717697236/se-2?accountid=49069)
- 513 23. Ghazi Zadeh L. Freeze-Dried Chitosan Platelet-Rich Plasma Mixtures for Knee
514 Meniscus Repair [Internet]. ProQuest Dissertations and Theses. [Canada -- Quebec,
515 CA]: Ecole Polytechnique, Montreal (Canada) PP - Canada -- Quebec, CA; 2018.
516 Available from: [https://www.proquest.com/dissertations-theses/freeze-dried-chitosan-](https://www.proquest.com/dissertations-theses/freeze-dried-chitosan-platelet-rich-plasma/docview/2506679949/se-2?accountid=49069)
517 [platelet-rich-plasma/docview/2506679949/se-2?accountid=49069](https://www.proquest.com/dissertations-theses/freeze-dried-chitosan-platelet-rich-plasma/docview/2506679949/se-2?accountid=49069)
- 518 24. Nimura A, Muneta T, Koga H, et al. Increased proliferation of human synovial
519 mesenchymal stem cells with autologous human serum: comparisons with bone
520 marrow mesenchymal stem cells and with fetal bovine serum. *Arthritis Rheum.*
521 2008;58(2):501-510. doi:10.1.
- 522 25. Nakamura K, Tsuji K, Mizuno M, Koga H, Muneta T, Sekiya I. Initial cell plating
523 density affects properties of human primary synovial mesenchymal stem cells. *J*
524 *Orthop Res.* 2019;37(6):1358-1367. doi:10.1002/jor.24112.
- 525 26. Ito K, Shimizu N, Watanabe K, et al. Analysis of viral infection by multiplex
526 polymerase chain reaction assays in patients with liver dysfunction. *Intern Med.*
527 2013;52(2):201-211. doi:10.2169/internalmedicine.52.8206.
- 528 27. Shimaya M, Muneta T, Ichinose S, Tsuji K, Sekiya I. Magnesium enhances adherence
529 and cartilage formation of synovial mesenchymal stem cells through integrins.
530 *Osteoarthritis Cartilage.* 2010;18(10):1300-1309. doi:10.1016/j.joca.2010.06.005.

- 531 28. Koga H, Shimaya M, Muneta T, et al. Local adherent technique for transplanting
532 mesenchymal stem cells as a potential treatment of cartilage defect. *Arthritis Res Ther.*
533 2008;10(4):R84. doi:10.1186/ar2460.
- 534 29. Kim SH, Ha CW, Park YB, Nam E, Lee JE, Lee HJ. Intra-articular injection of
535 mesenchymal stem cells for clinical outcomes and cartilage repair in osteoarthritis of
536 the knee: a meta-analysis of randomized controlled trials. *Arch Orthop Trauma Surg.*
537 2019;139.
- 538 30. Qiu M, Liu D, Fu Q. MiR-129-5p shuttled by human synovial mesenchymal stem cell-
539 derived exosomes relieves IL-1 β induced osteoarthritis via targeting HMGB1. *Life Sci*
540 [Internet]. 2021;269(36):118987. Available from:
541 <https://doi.org/10.1016/j.lfs.2020.118987>
- 542 31. Hernigou P, Bouthors C, Bastard C, Flouzat Lachaniette CH, Rouard H, Dubory A.
543 Subchondral bone or intra-articular injection of bone marrow concentrate
544 mesenchymal stem cells in bilateral knee osteoarthritis: what better postpone knee
545 arthroplasty at fift.
- 546 32. Saetan N, Honsawek S, Tanavalee A, et al. Relationship of plasma and synovial fluid
547 vascular endothelial growth factor with radiographic severity in primary knee
548 osteoarthritis. *Int Orthop.* 2014;38(5):1099-1104. doi:10.1007/s00264-013-2192-y.
- 549 33. Xu Z, He Z, Shu L, Li X, Ma M, Ye C. Intra-Articular Platelet-Rich Plasma Combined
550 With Hyaluronic Acid Injection for Knee Osteoarthritis Is Superior to Platelet-Rich
551 Plasma or Hyaluronic Acid Alone in Inhibiting Inflammation and Improving Pain and
552 Function [Internet]. Vol. 37, *Arthroscopy - Journal of Arthroscopic and Related*
553 *Surgery.* The Arthroscopy Association of North America; 2021. 903–915 p. Available

- 554 from: <https://doi.org/10.1016/j.arthro.2020.10.013>
- 555 34. Emadedin M, Aghdami N, Taghiyar L, Fazeli R, Moghadasali R, Jahangir S, et al.
556 Intra-articular injection of autologous mesenchymal stem cells in six patients with
557 knee Osteoarthritis. *Arch Iran Med.* 2012;15(7):422–8.
- 558 35. Jo CH, Chai JW, Jeong EC, Oh S, Shin JS, Shim H, et al. Intra-articular Injection of
559 Mesenchymal Stem Cells for the Treatment of Osteoarthritis of the Knee: A 2-Year
560 Follow-up Study. *Am J Sports Med.* 2017;45(12):2774–83.
- 561 36. Lamo-Espinosa JM, Mora G, Blanco JF, Granero-Moltó F, Nuñez-Córdoba JM,
562 Sánchez-Echenique C, et al. Intra-articular injection of two different doses of
563 autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the
564 treatment of knee osteoarthritis: Multicenter randomized controlled clinical trial (phase
565 I/II). *J Transl Med.* 2016 Aug 26;14(1).
- 566 37. Garza JR, Campbell RE, Tjoumakaris FP, et al. Clinical Efficacy of Intra-articular
567 Mesenchymal Stromal Cells for the Treatment of Knee Osteoarthritis: A Double-
568 Blinded Prospective Randomized Controlled Clinical Trial. *Am J Sports Med.*
569 2020;48(3):588-598. .
- 570 38. Jo CH, Lee YG, Shin WH, et al. Intra-articular injection of mesenchymal stem cells for
571 the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial [published
572 correction appears in *Stem Cells.* 2014;
573
574




Figure 1. PRISMA 2020 flow diagram.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Figure 2. Risk of Bias Assessment



Figure 4. Forest plot of VAS score between intervention vs control group

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Figure 6. Forest plot of WOMAC score between intervention and control group.